United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Choreo LLC

Choreo LLC lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 20.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,132 shares of the biotechnology company’s stock after selling 290 shares during the quarter. Choreo LLC’s holdings in United Therapeutics were worth $404,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. World Investment Advisors LLC purchased a new stake in shares of United Therapeutics in the third quarter valued at approximately $139,206,000. FMR LLC boosted its position in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Assetmark Inc. grew its stake in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares during the period. Franklin Resources Inc. increased its holdings in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec increased its holdings in shares of United Therapeutics by 32.5% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company’s stock valued at $123,181,000 after purchasing an additional 84,369 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $960,576.75. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 121,864 shares of company stock worth $44,516,965 over the last quarter. 11.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent analyst reports. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $370.74 on Thursday. The firm’s 50 day moving average price is $361.99 and its 200 day moving average price is $358.32. The firm has a market cap of $16.55 billion, a P/E ratio of 16.28, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $211.61 and a 1 year high of $417.82.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.